REFERENCES
1. Yaniv G, Twig G, Shor DB, et al. A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients. Autoimmun Rev. 2015;14:75-9.
2. Gómez-Bañuelos E, Fava A, Andrade F. An update on autoantibodies in systemic lupus erythematosus. Curr Opin Rheumatol. 2023;35:61-7.
3. Dema B, Charles N. Autoantibodies in SLE: specificities, isotypes and receptors. Antibodies. 2016;5:2.
4. Lou H, Ling GS, Cao X. Autoantibodies in systemic lupus erythematosus: from immunopathology to therapeutic target. J Autoimmun. 2022;132:102861.
5. Deshmukh US, Bagavant H, Fu SM. Role of anti-DNA antibodies in the pathogenesis of lupus nephritis. Autoimmun Rev. 2006;5:414-8.
6. Aringer M, Costenbader K, Daikh D, et al. 2019 European league against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71:1400-12.
7. Cohen AS, Reynolds WE, Franklin EC, et al. Preliminary criteria for the classification of systemic lupus erythematosus. Bull Rheum Dis. 1971;21:643-8.
8. Trimble RB, Townes AS, Robinson H, et al. Preliminary criteria for the classification of systemic lupus erythematosus (SLE). Evaluation in early diagnosed SLE and rheumatoid arthritis. Arthritis Rheum. 1974;17:184-8.
9. Passas CM, Wong RL, Peterson M, Testa MA, Rothfield NF. A comparison of the specificity of the 1971 and 1982 American Rheumatism Association criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1985;28:620-3.
11. Devreese KM. Antiphospholipid antibody testing and standardization. Int J Lab Hematol. 2014;36:352-63.
12. Meroni PL, Bizzaro N, Cavazzana I, Borghi MO, Tincani A. Automated tests of ANA immunofluorescence as throughput autoantibody detection technology: strengths and limitations. BMC Med. 2014;12:38.
13. Abeles AM, Abeles M. The clinical utility of a positive antinuclear antibody test result. Am J Med. 2013;126:342-8.
14. Li X, Liu X, Cui J, et al. Epidemiological survey of antinuclear antibodies in healthy population and analysis of clinical characteristics of positive population. J Clin Lab Anal. 2019;33:e22965.
15. Zharkova O, Celhar T, Cravens PD, Satterthwaite AB, Fairhurst AM, Davis LS. Pathways leading to an immunological disease: systemic lupus erythematosus. Rheumatology. 2017;56:i55-66.
16. Pieterse E, van der Vlag J. Breaking immunological tolerance in systemic lupus erythematosus. Front Immunol. 2014;5:164.
17. Hargraves MM, Richmond H, Morton R. Presentation of two bone marrow elements; the tart cell and the L.E. cell. Proc Staff Meet Mayo Clin. 1948;23:25-8.
18. Sundberg RD, Lick NB. L. E. cells in the blood in acute disseminated lupus erythematosus. J Invest Dermatol. 1949;12:83.
20. Mahajan A, Herrmann M, Muñoz LE. Clearance deficiency and cell death pathways: a model for the pathogenesis of SLE. Front Immunol. 2016;7:35.
21. Mistry P, Kaplan MJ. Cell death in the pathogenesis of systemic lupus erythematosus and lupus nephritis. Clin Immunol. 2017;185:59-73.
22. Botto M, Dell'Agnola C, Bygrave AE, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet. 1998;19:56-9.
23. Stegert M, Bock M, Trendelenburg M. Clinical presentation of human C1q deficiency: how much of a lupus? Mol Immunol. 2015;67:3-11.
26. Guo J, Gao Y, Wang Y, et al. Investigation of C1-complex regions reveals new C1Q variants associated with protection from systemic lupus erythematosus, and affect its transcript abundance. Sci Rep. 2018;8:8048.
27. Al-Mayouf SM, Sunker A, Abdwani R, et al. Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus. Nat Genet. 2011;43:1186-8.
28. Engavale M, Hernandez CJ, Infante A, et al. Deficiency of macrophage-derived Dnase1L3 causes lupus-like phenotypes in mice. J Leukoc Biol. 2023;114:547-56.
29. Soni C, Perez OA, Voss WN, et al. Plasmacytoid dendritic cells and type I interferon promote extrafollicular B cell responses to extracellular self-DNA. Immunity. 2020;52:1022-38.e7.
30. Gomez-Bañuelos E, Yu Y, Li J, et al. Affinity maturation generates pathogenic antibodies with dual reactivity to DNase1L3 and dsDNA in systemic lupus erythematosus. Nat Commun. 2023;14:1388.
31. Hartl J, Serpas L, Wang Y, et al. Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus. J Exp Med. 2021;218:e20201138.
32. Lood C, Blanco LP, Purmalek MM, et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat Med. 2016;22:146-53.
33. Giaglis S, Daoudlarian D, Voll RE, Kyburz D, Venhoff N, Walker UA. Circulating mitochondrial DNA copy numbers represent a sensitive marker for diagnosis and monitoring of disease activity in systemic lupus erythematosus. RMD Open. 2021;7:e002010.
34. Ide T, Tsutsui H, Hayashidani S, et al. Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res. 2001;88:529-35.
35. Davidson SM, Yellon DM. Mitochondrial DNA damage, oxidative stress, and atherosclerosis: where there is smoke there is not always fire. Circulation. 2013;128:681-3.
36. Caielli S, Athale S, Domic B, et al. Oxidized mitochondrial nucleoids released by neutrophils drive type I interferon production in human lupus. J Exp Med. 2016;213:697-713.
37. Yousefi S, Mihalache C, Kozlowski E, Schmid I, Simon HU. Viable neutrophils release mitochondrial DNA to form neutrophil extracellular traps. Cell Death Differ. 2009;16:1438-44.
38. Hakkim A, Fürnrohr BG, Amann K, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA. 2010;107:9813-8.
39. Lee HT, Wu TH, Lin CS, et al. The pathogenesis of systemic lupus erythematosus - From the viewpoint of oxidative stress and mitochondrial dysfunction. Mitochondrion. 2016;30:1-7.
40. Shah D, Sah S, Wanchu A, Wu MX, Bhatnagar A. Altered redox state and apoptosis in the pathogenesis of systemic lupus erythematosus. Immunobiology. 2013;218:620-7.
41. Pravda J. Systemic lupus erythematosus: pathogenesis at the functional limit of redox homeostasis. Oxid Med Cell Longev. 2019;2019:1651724.
42. Urbonaviciute V, Luo H, Sjöwall C, Bengtsson A, Holmdahl R. Low production of reactive oxygen species drives systemic lupus erythematosus. Trends Mol Med. 2019;25:826-35.
43. Bengtsson AA, Pettersson Å, Wichert S, et al. Low production of reactive oxygen species in granulocytes is associated with organ damage in systemic lupus erythematosus. Arthritis Res Ther. 2014;16:R120.
44. Lennicke C, Cochemé HM. Redox metabolism: ROS as specific molecular regulators of cell signaling and function. Mol Cell. 2021;81:3691-707.
45. Villalpando-Rodriguez GE, Gibson SB. Reactive oxygen species (ROS) regulates different types of cell death by acting as a rheostat. Oxid Med Cell Longev. 2021;2021:9912436.
46. Wang B, Wang Y, Zhang J, et al. ROS-induced lipid peroxidation modulates cell death outcome: mechanisms behind apoptosis, autophagy, and ferroptosis. Arch Toxicol. 2023;97:1439-51.
47. Perricone C, De Carolis C, Perricone R. Glutathione: a key player in autoimmunity. Autoimmun Rev. 2009;8:697-701.
48. Taysi S, Gul M, Sari RA, Akcay F, Bakan N. Serum oxidant/antioxidant status of patients with systemic lupus erythematosus. Clin Chem Lab Med. 2002;40:684-8.
49. Tewthanom K, Janwityanuchit S, Totemchockchyakarn K, Panomvana D. Correlation of lipid peroxidation and glutathione levels with severity of systemic lupus erythematosus: a pilot study from single center. J Pharm Pharm Sci. 2008;11:30-4.
50. Shah D, Sah S, Nath SK. Interaction between glutathione and apoptosis in systemic lupus erythematosus. Autoimmun Rev. 2013;12:741-51.
52. Li P, Jiang M, Li K, et al. Glutathione peroxidase 4-regulated neutrophil ferroptosis induces systemic autoimmunity. Nat Immunol. 2021;22:1107-17.
53. Mills EL, Kelly B, O'Neill LAJ. Mitochondria are the powerhouses of immunity. Nat Immunol. 2017;18:488-98.
54. West AP, Shadel GS. Mitochondrial DNA in innate immune responses and inflammatory pathology. Nat Rev Immunol. 2017;17:363-75.
55. Hu MM, Shu HB. Mitochondrial DNA-triggered innate immune response: mechanisms and diseases. Cell Mol Immunol. 2023;20:1403-12.
56. Szklarczyk R, Huynen MA. Mosaic origin of the mitochondrial proteome. Proteomics. 2010;10:4012-24.
57. Roger AJ, Muñoz-Gómez SA, Kamikawa R. The origin and diversification of mitochondria. Curr Biol. 2017;27:R1177-92.
58. Becker YLC, Gagné JP, Julien AS, et al. Identification of Mitofusin 1 and complement component 1q subcomponent binding protein as mitochondrial targets in systemic lupus erythematosus. Arthritis Rheumatol. 2022;74:1193-203.
59. Caielli S, Cardenas J, de Jesus AA, et al. Erythroid mitochondrial retention triggers myeloid-dependent type I interferon in human SLE. Cell. 2021;184:4464-79.e19.
60. Caielli S, Balasubramanian P, Rodriguez-Alcazar J, et al. Type I IFN drives unconventional IL-1β secretion in lupus monocytes. Immunity. 2024;57:2497-513.e12.
61. Durieux J, Wolff S, Dillin A. The cell-non-autonomous nature of electron transport chain-mediated longevity. Cell. 2011;144:79-91.
62. Long YC, Tan TM, Takao I, Tang BL. The biochemistry and cell biology of aging: metabolic regulation through mitochondrial signaling. Am J Physiol Endocrinol Metab. 2014;306:E581-91.
63. Luan HH, Wang A, Hilliard BK, et al. GDF15 is an inflammation-induced central mediator of tissue tolerance. Cell. 2019;178:1231-44.e11.
64. Dogon G, Rigal E, Potel E, et al. Growth/differentiation factor 15 (GDF15) expression in the heart after myocardial infarction and cardioprotective effect of pre-ischemic rGDF15 administration. Sci Rep. 2024;14:12949.
65. Xu WD, Huang Q, Yang C, Li R, Huang AF. GDF-15: a potential biomarker and therapeutic target in systemic lupus erythematosus. Front Immunol. 2022;13:926373.
66. Lorenz G, Ribeiro A, von Rauchhaupt E, et al. GDF15 suppresses lymphoproliferation and humoral autoimmunity in a murine model of systemic lupus erythematosus. J Innate Immun. 2022;14:673-89.
67. Ye D, Liu B, He Z, et al. Assessing the associations of growth differentiation factor 15 with rheumatic diseases using genetic data. Clin Epidemiol. 2021;13:245-52.
68. Zorova LD, Popkov VA, Plotnikov EY, et al. Mitochondrial membrane potential. Anal Biochem. 2018;552:50-9.
69. Gergely P, Grossman C, Niland B, et al. Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheumatism. 2002;46:175-90.
70. Perl A, Gergely P Jr, Banki K. Mitochondrial dysfunction in T cells of patients with systemic lupus erythematosus. Int Rev Immunol. 2004;23:293-313.
71. Sumikawa MH, Iwata S, Zhang M, et al. An enhanced mitochondrial function through glutamine metabolism in plasmablast differentiation in systemic lupus erythematosus. Rheumatology. 2022;61:3049-59.
72. Gkirtzimanaki K, Kabrani E, Nikoleri D, et al. IFNα impairs autophagic degradation of mtDNA promoting autoreactivity of SLE monocytes in a STING-dependent fashion. Cell Rep. 2018;25:921-33.e5.
74. Yennemadi AS, Keane J, Leisching G. Mitochondrial bioenergetic changes in systemic lupus erythematosus immune cell subsets: contributions to pathogenesis and clinical applications. Lupus. 2023;32:603-11.
75. Aso K, Kono M, Kanda M, et al. Itaconate ameliorates autoimmunity by modulating T cell imbalance via metabolic and epigenetic reprogramming. Nat Commun. 2023;14:984.
76. Patiño-Martinez E, Nakabo S, Jiang K, et al. The aconitate decarboxylase 1/itaconate pathway modulates immune dysregulation and associates with cardiovascular disease markers and disease activity in systemic lupus erythematosus. J Immunol. 2024;213:419-34.
77. Blanco LP, Patino-Martinez E, Nakabo S, et al. Modulation of the itaconate pathway attenuates murine lupus. Arthritis Rheumatol. 2022;74:1971-83.
78. O'Carroll SM, Peace CG, Toller-Kawahisa JE, et al. Itaconate drives mtRNA-mediated type I interferon production through inhibition of succinate dehydrogenase. Nat Metab. 2024;6:2060-9.
79. Buang N, Tapeng L, Gray V, et al. Type I interferons affect the metabolic fitness of CD8+ T cells from patients with systemic lupus erythematosus. Nat Commun. 2021;12:1980.
80. Toelch U, Dolan RJ. Informational and normative influences in conformity from a neurocomputational perspective. Trends Cogn Sci. 2015;19:579-89.
81. Rönnblom L, Leonard D. Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci Med. 2019;6:e000270.
82. Postal M, Vivaldo JF, Fernandez-Ruiz R, Paredes JL, Appenzeller S, Niewold TB. Type I interferon in the pathogenesis of systemic lupus erythematosus. Curr Opin Immunol. 2020;67:87-94.
83. Tanaka Y, Kusuda M, Yamaguchi Y. Interferons and systemic lupus erythematosus: pathogenesis, clinical features, and treatments in interferon-driven disease. Mod Rheumatol. 2023;33:857-67.
84. Psarras A, Wittmann M, Vital EM. Emerging concepts of type I interferons in SLE pathogenesis and therapy. Nat Rev Rheumatol. 2022;18:575-90.
85. Kennedy WP, Maciuca R, Wolslegel K, et al. Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE. Lupus Sci Med. 2015;2:e000080.
86. Catalina MD, Bachali P, Geraci NS, Grammer AC, Lipsky PE. Gene expression analysis delineates the potential roles of multiple interferons in systemic lupus erythematosus. Commun Biol. 2019;2:140.
87. El-Sherbiny YM, Md Yusof MY, Psarras A, et al. B cell Tetherin: a flow cytometric cell-specific assay for response to type I interferon predicts clinical features and flares in systemic lupus erythematosus. Arthritis Rheumatol. 2020;72:769-79.
88. Barrat FJ, Crow MK, Ivashkiv LB. Interferon target-gene expression and epigenomic signatures in health and disease. Nat Immunol. 2019;20:1574-83.
89. Northcott M, Jones S, Koelmeyer R, et al. Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis. Lupus Sci Med. 2022;9:e000625.
90. Banchereau R, Hong S, Cantarel B, et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell. 2016;165:551-65.
91. El-Sherbiny YM, Psarras A, Md Yusof MY, et al. A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features. Sci Rep. 2018;8:5793.
92. Md Yusof MY, Psarras A, El-Sherbiny YM, et al. Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status. Ann Rheum Dis. 2018;77:1432-9.
93. Rector I, Owen KA, Bachali P, et al. Differential regulation of the interferon response in systemic lupus erythematosus distinguishes patients of Asian ancestry. RMD Open. 2023;9:e003475.
94. Lewis MJ, Jawad AS. The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus. Rheumatology. 2017;56:i67-77.
95. Parodis I, Lanata C, Nikolopoulos D, Blazer A, Yazdany J. Reframing health disparities in SLE: a critical reassessment of racial and ethnic differences in lupus disease outcomes. Best Pract Res Clin Rheumatol. 2023;37:101894.
96. Joseph S, George NI, Green-Knox B, et al. Epigenome-wide association study of peripheral blood mononuclear cells in systemic lupus erythematosus: identifying DNA methylation signatures associated with interferon-related genes based on ethnicity and SLEDAI. J Autoimmun. 2019;96:147-57.
97. Carter LM, Md Yusof MY, Wigston Z, et al. Blood RNA-sequencing across the continuum of ANA-positive autoimmunity reveals insights into initiating immunopathology. Ann Rheum Dis. 2024;83:1322-34.
98. Chiche L, Jourde-Chiche N, Whalen E, et al. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol. 2014;66:1583-95.
99. Hile GA, Gudjonsson JE, Kahlenberg JM. The influence of interferon on healthy and diseased skin. Cytokine. 2020;132:154605.
100. Sarkar MK, Hile GA, Tsoi LC, et al. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa. Ann Rheum Dis. 2018;77:1653-64.
101. Psarras A, Alase A, Antanaviciute A, et al. Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity. Nat Commun. 2020;11:6149.
102. Harley IT, Niewold TB, Stormont RM, et al. The role of genetic variation near interferon-kappa in systemic lupus erythematosus. J Biomed Biotechnol. 2010;2010:1-11.
103. Parodis I, Girard-Guyonvarc'h C, Arnaud L, et al. EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis. Ann Rheum Dis. 2024;83:720-9.
104. Duarte-García A, Fang H, To CH, Magder LS, Petri M. Seasonal variation in the activity of systemic lupus erythematosus. J Rheumatol. 2012;39:1392-8.
105. Chiche L, Jourde N, Ulmann C, et al. Seasonal variations of systemic lupus erythematosus flares in southern France. Eur J Intern Med. 2012;23:250-4.
106. Abdelaziz TS, Rakha NK, Fayad T, Mahmoud GA, Fayed A, Hammad H. Seasonal variation of lupus nephritis in a cohort of Egyptian patients. Clin Rheumatol. 2023;42:1013-8.
107. Skopelja-Gardner S, Tai J, Sun X, et al. Acute skin exposure to ultraviolet light triggers neutrophil-mediated kidney inflammation. Proc Natl Acad Sci USA. 2021;118:e2019097118.
108. Billi AC, Ma F, Plazyo O, et al. Nonlesional lupus skin contributes to inflammatory education of myeloid cells and primes for cutaneous inflammation. Sci Transl Med. 2022;14:eabn2263.
109. Psarras A, Vital EM. Keratinocytes: from passive targets to active mediators of systemic autoimmunity. Sci Transl Med. 2022;14:eabo3961.
110. Lazear HM, Schoggins JW, Diamond MS. Shared and distinct functions of type I and type III interferons. Immunity. 2019;50:907-23.
111. Chodisetti SB, Fike AJ, Domeier PP, et al. Type II but not type I IFN signaling is indispensable for TLR7-promoted development of autoreactive B cells and systemic autoimmunity. J Immunol. 2020;204:796-809.
112. Alase AA, El-Sherbiny YM, Vital EM, Tobin DJ, Turner NA, Wittmann M. IFNλ stimulates MxA production in human dermal fibroblasts via a MAPK-dependent STAT1-independent mechanism. J Invest Dermatol. 2015;135:2935-43.
113. Chen JY, Wang CM, Chen TD, et al. Interferon-λ3/4 genetic variants and interferon-λ3 serum levels are biomarkers of lupus nephritis and disease activity in Taiwanese. Arthritis Res Ther. 2018;20:193.
114. Brown GJ, Cañete PF, Wang H, et al. TLR7 gain-of-function genetic variation causes human lupus. Nature. 2022;605:349-56.
115. Stremenova Spegarova J, Sinnappurajar P, Al Julandani D, et al. A de novo TLR7 gain-of-function mutation causing severe monogenic lupus in an infant. J Clin Invest. 2024;134:e179193.
116. Al-Azab M, Idiiatullina E, Liu Z, et al. Genetic variants in UNC93B1 predispose to childhood-onset systemic lupus erythematosus. Nat Immunol. 2024;25:969-80.
117. Pearson D, Morand E, Wenzel J, et al. Randomized, placebo-controlled phase II study of Enpatoran, a small molecule toll-like receptor 7/8 inhibitor, in cutaneous lupus erythematosus: results from cohort A. J Rheumatol. 2025;52:11.1-11.
118. Graham RR, Ortmann W, Rodine P, et al. Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE. Eur J Hum Genet. 2007;15:823-30.
119. Miglioranza Scavuzzi B, van Drongelen V, Kaur B, et al. The lupus susceptibility allele DRB1*03:01 encodes a disease-driving epitope. Commun Biol. 2022;5:751.
120. Contini P, Murdaca G, Puppo F, Negrini S. HLA-G expressing immune cells in immune mediated diseases. Front Immunol. 2020;11:1613.
121. Martín-Villa JM, Vaquero-Yuste C, Molina-Alejandre M, et al. HLA-G: too much or too little? Role in cancer and autoimmune disease. Front Immunol. 2022;13:796054.
122. Tsang-A-Sjoe MW, Nagelkerke SQ, Bultink IE, et al. Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis. Rheumatology. 2016;55:939-48.
123. Brown EE, Edberg JC, Kimberly RP. Fc receptor genes and the systemic lupus erythematosus diathesis. Autoimmunity. 2007;40:567-81.
124. Chalayer E, Gramont B, Zekre F, et al. Fc receptors gone wrong: a comprehensive review of their roles in autoimmune and inflammatory diseases. Autoimmun Rev. 2022;21:103016.
125. Iruretagoyena M, Hirigoyen D, Naves R, Burgos PI. Immune response modulation by vitamin D: role in systemic lupus erythematosus. Front Immunol. 2015;6:513.
126. Dall'Ara F, Cutolo M, Andreoli L, Tincani A, Paolino S. Vitamin D and systemic lupus erythematous: a review of immunological and clinical aspects. Clin Exp Rheumatol. 2018;36:153-62.
127. Vieira JRP, Rezende ATO, Fernandes MR, da Silva NA. Intestinal microbiota and active systemic lupus erythematosus: a systematic review. Adv Rheumatol. 2021;61:42.
